News

Australian scientists have pinpointed likely ‘cells-of-origin’, the source cells that can grow into breast cancer, in women carrying a faulty BRCA2 gene who are at high risk of developing the disease. Credit: Must credit Dr Bianca Capaldo, WEHI Australian scientists have pinpointed likely ‘cells-of-origin’, the

About one hundred so-called cancer predisposition genes (CPGs) are known. The probability of developing cancer is greater in individuals who inherit certain altered variants of one of these genes. “But these 100 genes account for only about 10% of cancer cases. The vast majority of

T cell surface markers CD4 and LAG-3 are related proteins that promote and inhibit cell activity, respectively. However, although LAG-3 starts to be appreciated as an “immune checkpoint” molecule that can be targeted in cancer immunotherapy, only CD4 is well understood. Now, a comprehensive study

“Identification and validation of novel and targetable metabolic weaknesses in AML is ongoing.” Credit: 2023 Roma et al. “Identification and validation of novel and targetable metabolic weaknesses in AML is ongoing.” BUFFALO, NY- January 16, 2024 – A new editorial paper was published in Oncotarget’s

New study by Hebrew University reveals that a significant proportion (over one fifth) of human pluripotent stem cell samples that can be used in regenerative medicine possess cancer-related mutations, with the majority acquired during their propagation in culture. The findings underscore the importance of regular

Recently, a team of South Korean researchers led by nuclear medicine physician and Professor YUN Mijin from Severance Hospital in collaboration with Director C. Justin LEE of the Center for Cognition and Sociality within the Institute for Basic Science (IBS) made a new discovery that

Breast cancer is the most common cancer in women. The development of breast cancer often originates from epithelial cells in the mammary gland – the very cells that specialise in milk production during and after pregnancy. A team of researchers from Friedrich Schiller University Jena

The presence of the T790M mutation during first or second-generation EGFR-TKI treatments is observed in 50-60% of patients. This mutation hinders the drug’s binding to the mutant EGFR protein. Osimertinib, however, can covalently bind to the T790M and cysteine-797 (C797) residue at the protein’s ATP

Monoclonal antibodies (mAbs) are laboratory-designed proteins that mimic the immune system’s antibodies. To date, many therapeutic mAbs belonging to the immunoglobulin G (IgG) class of antibodies, have been approved for the treatment of cancer and autoimmune diseases. Cell lines such as the Chinese hamster ovary

Bladder cancer has one of the highest incidence rates in the world and ranks as the fourth most common tumour in men. Despite its relatively low mortality rate, nearly half of bladder tumours resurface within 5 years, requiring ongoing patient monitoring. Frequent hospital visits and